Orlistat

證據等級: L5

預測適應症: 10 個

Orlistat: From Obesity Management to Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)

Note on indication selection: TxGNN’s top-ranked prediction by raw score is hypervitaminosis (99.4%), but the evidence pack’s own rationale flags this as a known adverse effect of lipase inhibition, not a viable treatment target — and it has zero supporting trials or literature (L5/Hold). This report instead focuses on fatty liver disease (NAFLD/NASH), the only candidate among the 10 predicted indications with completed clinical trials, matching publications, and an actionable recommendation.

One-Sentence Summary

Orlistat is a gastric/pancreatic lipase inhibitor originally used for weight management in obesity. TxGNN predicts potential efficacy for non-alcoholic fatty liver disease (NAFLD/NASH), with 2 directly relevant completed Phase 4 clinical trials (and corresponding peer-reviewed publications identified during evidence review) supporting this direction.

Quick Overview

Item	Content
Original Indication	Obesity / weight management (well-established use; not recorded in this evidence pack’s structured fields)
Predicted New Indication	Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
TxGNN Prediction Score	85.26%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed original mechanism-of-action data was not separately documented in this evidence pack. Based on the repurposing analysis, Orlistat inhibits gastric and pancreatic lipase, reducing dietary fat absorption by approximately 30% — the established pharmacological basis for its use in weight management.

This mechanism maps directly onto NAFLD/NASH pathophysiology: reduced fat absorption lowers hepatic fat delivery and contributes to weight loss, both of which address the lipotoxicity and insulin resistance that drive fatty liver disease. Obesity is itself a primary risk factor for NAFLD, so a drug that treats obesity has a plausible, direct route to benefiting fatty liver outcomes rather than a purely coincidental network association.

Two completed Phase 4 trials tested this hypothesis directly rather than as a downstream inference: NCT00207311 and NCT00160407 both enrolled overweight patients with hepatic steatosis/NASH and used orlistat as the active intervention.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00207311	Phase 4	Completed	30	RCT of orlistat in patients with >33% hepatic steatosis or NASH plus chronic hepatitis C. Corresponds to published RCT (PMID 16630771) showing significant ALT and ultrasound-graded steatosis improvement; insulin resistance and fibrosis signals warrant monitoring. [Relevance: A]
NCT00160407	Phase 4	Completed	50	Orlistat (Xenical) in overweight patients with NASH. Corresponds to published RCT (PMID 19053049): enhanced weight loss with improvement in necroinflammatory and fibrotic liver changes. [Relevance: A]
NCT00001723	Phase 2	Completed	200	Safety/efficacy of orlistat in adolescents with obesity-related comorbidities. Supports the obesity→liver pathway but was not a NAFLD-primary-endpoint trial. [Relevance: B]
NCT04270656	N/A	Completed	46	Studies insulin pump therapy (not orlistat) in T2D patients with NAFLD — same disease category only, not direct orlistat evidence. [Relevance: C]
NCT05934110	Phase 2	Unknown	320	Compares EMP16 + acarbose combination against conventional orlistat and placebo; orlistat’s role as comparator (not primary intervention) could not be confirmed from the available summary. [Relevance: C]
NCT06501326	Phase 4	Unknown	102	Studies liraglutide (not orlistat) in obesity with MAFLD — different drug, listed for category context only. [Relevance: C]
NCT07437001	N/A	Not yet recruiting	60	Studies electroacupuncture (not orlistat) for central obesity and fatty liver — not direct orlistat evidence. [Relevance: C]

No ANZCTR-registered trials were identified for this indication in the evidence pack.

Literature Evidence

The evidence pack’s structured literature collector returned no results specifically indexed against this indication. However, the repurposing rationale references two externally-identified publications corresponding to the trials above — PMID 16630771 (Zelber-Sagi et al., 2006, RCT, corresponds to NCT00207311) and PMID 19053049 (RCT, corresponds to NCT00160407) — which were confirmed during evidence review but are not yet formally captured in this dataset’s literature table. These should be added to the formal evidence base before further progression.

Australia Market Information

Orlistat is not currently marketed in Australia under this evidence pack (0 ARTG entries recorded). No product listing, dosage form, or approved indication text is available to summarise.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack did not return usable data on key warnings, contraindications, or drug–drug interactions (DDI query status: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 4 RCTs directly tested orlistat in NAFLD/NASH populations, with corresponding publications showing measurable improvement in hepatic steatosis, ALT, and (in one trial) necroinflammatory/fibrotic changes — meaningfully stronger evidence than the other 9 TxGNN candidates in this pack, all of which are L5/Hold with no supporting trials or literature. However, orlistat is not currently marketed in Australia and this evidence pack lacks safety/DDI data, so guardrails are needed before advancing.

To proceed, the following is needed:

TGA Product Information — key warnings, contraindications, DDI profile (currently blocking data gap, DG001)
Formal mechanism-of-action documentation from DrugBank (DG002)
Formal incorporation of PMID 16630771 and PMID 19053049 into the structured literature evidence base
Clarification of the ARTG registration pathway, since the drug is not currently marketed in Australia
Independent assessment of fibrosis/insulin-resistance safety signals noted in NCT00207311 before any clinical translation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.